

Implementing Statistical Innovations in the Pharmaceutical Industry:

Moving the needle on use of Bayesian methods



Nicky Best
Statistics and Data Science Innovation Hub, GSK



### Successful implementation of Bayesian approaches at GSK

GSK's Boostrix for pertussis cleared by FDA for use in pregnancy



### FDA Approved Product Label

BDB primary analysis of real-world data led to the inclusion of BDB results in the FDA-approved label for maternal Boostrix vaccination



### Pediatric Efficacy Extrapolation

BDB in a pediatric efficacy trial facilitated FDA approval of Belimumab for pediatric lupus

BDB is routinely proposed for clinical efficacy extrapolation in paediatric studies at GSK





### **CDE Approved Product Label**

BDB design used for a confirmatory bridging trial that supported the approval of Mepolizumab for severe asthma in China.



#### **Governance Boards**

Bayesian quantitative decision making (QDM) framework is embedded as a core part of GSK's Clinical Development Planning and Governance processes



### Road to "commercialisation": Bayesian Quantitative Decision Making





### Road to "commercialisation": Bayesian Dynamic Borrowing (BDB)



Robust Meta-Analytic-Predictive Priors in Clinical Trials with Historical Control Information

Heinz Schmidli ™, Sandro Gsteiger, Satrajit Roychoudhury, Anthony O'Hagan, David Spiegelhalter, Beat Neuenschwander Belimumab Benefits Kids With SLE, Data Confirm - First placebo-controlled trial shows efficacy, safety in pediatric lupus patients





Qualification of novel methodologies for medicine development



- Daprodustat Type C meeting
- Belimumab Information Request



**Historical Data SIG** 



Statistics in Biopharmaceutical Research

Beyond the Classical Type I Error: Bayesian Metrics for **Bayesian Designs Using Informative Priors** 

Nicky Best, Maxine Aiimi, Beat Neuenschwander, Gaëlle Saint-Hilary & Simon Wandelon behalf of the PSI/EFSPI special interest group "Historical



Assessing efficacy in important subgroups in confirmatory trials: An example using Bayesian dynamic borrowing

Nicky Best, Robert G. Price, Isabelle I, Pouliquen, Oliver N. Keene

R&D Data Hub > Capabilities > Bayesian Dynamic Borrowing



Package 'beastt'

February 24, 2025



#### Bayesian Dynamic Borrowing Technical Training

There is enormous potential to boost the decision-making power of our clinical trials if we are smart about how and when to re-use clinical data. It can help us to increase the precision of our treatment effect estimates or reduce the number of patients, costs and timelines of our clinical development programmes.

This course is aimed at Biostatistics statisticians applying QDM principles. Join us to explore how we can use historical information to design more efficient clinical trial pri





R&D – Bayesian Dynamic Borrowing guidance and resources Advancing the optimal use of Bayesian dynamic borrowing for research & developmen



in pregnancy

GSK's Boostrix for pertussis cleared by FDA for use



eosinophilic asthma gains approval in China

The Nucala antibody targeting IL-5 was initially approved in the US for severe asthma with an eosinophilic phenotype.







# Ingredients for Success (1)

A good idea





business A problem to solve



### Ingredients for Success (2)

# A good idea



# A good idea solution



IAIN PAPER ② Open Access ◎ ④ ⑤ ⑤

Conditional assurance: the answer to the questions that hould be asked within drug development

Statistics in Biopharmaceutical Research

Beyond the Classical Type I Error: Bayesian Metrics for Bayesian Designs Using Informative Priors

Nicky Best, Maxine Ajimi, Beat Neuenschwander, Gaëlle Saint-Hilary & Simon Wandelon behalf of the PSI/EFSPI special interest group "Historical Data"



ssessing efficacy in important subgroups in confirmator rials: An example using Bayesian dynamic borrowing



### Ingredients for Success (3)

# Adoption







First Follower: Leadership Lessons from Dancing Guy



### Ingredients for Success (4)



QDM Tools Hub

Home

#### **Evolving QDM**

QDM R

Rethinking QDM and Engaging with the Community

AUTHOR PUBLISHED

Ben Arancibia November 11, 2024


QDM has gone through different phases and the QDM development team is excited for a revamp. This revamp is focused on making sure Clinical Statistics knows and understands the scope of all current tools – as well as ensuring that the community can effectively steer the future development of our tools.

Below is a list of the current known tools that are available to use for QDM.

Tool Name	Description	URL
QDM Tools	R package for deriving conditional and unconditional	https://probable-guide-
	nrohabilities of success for standard designs. Users are able to	6900873 nades dithish in/



### Innovation in a Regulated Environment





## Final thoughts

# Commercialising Innovation is a Team Science



